DNA X, Inc. (SONM) Stock Price & Analysis
DNA X, Inc. (SONM) closed at USD 3.08 on Friday, October 23, 2026, down 3.47% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.08; the Oct 23, 2026 session ranged USD 3.08–3.25 on volume of 2,807 shares. Market capitalization is —, with a 52-week range of USD 2.52–12.3 (NCM). Source: Nexqual, retrieved October 24, 2026 at 13:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SONM.md
Key facts (SONM)
- Total return with dividends: 1Y -75.7% vs S&P 500 +13.4%; 5Y -99.3% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SONM)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $54.6M | $69.8M | $93.6M | $58.3M | — | — |
| Gross profit | $6.4M | $11.6M | $19.3M | $9.9M | — | — |
| Operating income | -$38.0M | -$14.3M | $513K | -$3.1M | -$5.4M | -$4.2M |
| Net income | -$38.6M | -$14.1M | -$90K | -$33.6M | -$20.7M | -$8.5M |
| EPS (diluted) | -$734.40 | -$88.20 | -$0.36 | -$128.37 | -$28.58 | — |
| Free cash flow | -$38.5M | -$12.4M | -$4.1M | -$8.7M | — | — |
| Gross margin | 11.8% | 16.6% | 20.6% | 17.0% | — | — |
| Operating margin | -69.6% | -20.5% | 0.5% | -5.3% | — | — |
| Net margin | -70.8% | -20.2% | -0.1% | -57.7% | — | — |
| Revenue growth | -14.7% | +28.0% | +34.1% | -37.7% | — | — |
| Cash + short-term investments | $11.2M | $13.2M | $9.4M | $5.3M | $1.3M | — |
| Total debt | $214K | — | — | — | $10.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SONM)
Total return (dividends reinvested) (SONM)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -75.7% | -99.3% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -75.8% | -62.4% |
| Volatility (annualized) | 122.9% | 112.0% |
| Max drawdown | -78.3% (Oct 2025→Dec 2025) | -99.3% (Oct 2021→Dec 2025) |
SONM revenue by product line (quarter ended Sep 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Smart Phones | $8.1M | 50.0% | +1.9% |
| Connected Solutions | $4.0M | 24.7% | +8063.3% |
| Feature Phones | $3.8M | 23.4% | -43.9% |
| Accessories & Other | $305,000 | 1.9% | +29.2% |
| Total revenue | $16.2M | 100% | — |
SONM revenue by region (quarter ended Sep 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $11.8M | 72.5% | +0.8% |
| Canada | $2.6M | 16.1% | -17.7% |
| Europe & Middle East | $1.8M | 11.2% | +2268.8% |
| Asia Pacific | $10,000 | 0.1% | -89.8% |
| Total revenue | $16.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
SONM customer concentration
In the period ended Sep 30, 2025, 2 direct customers each accounted for at least 10% (31%, 20%) of revenue, per the company's 10-Q filed Oct 31, 2025. The company does not name them.
SONM company outlook (results filed May 20, 2026)
- “We expect general & administrative expenses to be much lower in the next few quarters because we have downsized the organization and we have completed our annual audit. ● Cash Position: We ended the quarter with $1.2 million in cash from continuing operations.”
Quoted word-for-word from the SEC 8-K results press release.
SONM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Mar 2025) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2025) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 13:34 UTC)
| Price | USD 3.08 |
|---|---|
| Change | ▼ 3.47% (down) |
| Previous Close | USD 3.08 |
| Open | USD 3.08 |
| Day Range | USD 3.08 – 3.25 |
| 52-Week Range | USD 2.52 – 12.3 |
| Volume | 2,807 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (SONM)
Nexqual's technical model rates SONM "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 13:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.1 (neutral) |
| vs SMA50 | Below (USD 3.49) |
| MACD | -0.15 (negative) |
Earnings (SONM)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-09-30 | USD -9.36 vs est -11.88 ▲ beat |
| 2024-06-30 | USD -25.38 vs est -9.72 ▼ miss |
| 2024-03-31 | USD -12.6 vs est -5.4 ▼ miss |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financials & Fundamentals (SONM)
| Total Revenue | $-11.19M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +54.16% |
| Profit Margin | +0.00% |
| Current Ratio | 0.57 |
| Total Cash | $900,000 |
| Total Debt | $2.40M |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Ownership (SONM)
| Insider Ownership | +34.77% |
|---|---|
| Institutional Ownership | +6.74% |
| Shares Outstanding | 1.49M |
| Float | 1.01M |
| Short % of Float | +1.40% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
From DNA X, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed customizations to standard software that we believe makes it difficult for others to duplicate our platform.
- Our platform allows users to execute strategies between pairs of cryptocurrencies that allow them to swap between the currencies as the prices diverge or converge.
- We are developing products to increase the number of cryptocurrencies that are available for trading on our platform and products the Company expects to bring in additional customers and drive additional revenue from commissions and fees. any bugs or performance issues.
- We may use social media and traditional media to market our platform to potential customers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FAMI | Farmmi, Inc. Ordinary Shares | USD 0.11 | ▼ 2.91% |
| XTKGF | X3 Holdings Co., Ltd. | USD 0.01 | ▲ 0% |
| GRNQ | Greenpro Capital Corp. | USD 7.8 | ▲ 9.09% |
| SXTC | China SXT Pharmaceuticals, Inc. | USD 0.04 | ▼ 14.58% |
| BIMI | BIMI International Medical Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 13:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt